Covid-19: Pfizer, CornoaVac vaccine linked to heart inflammation risk in adolescents
Hong Kong: Despite low absolute risk, there is an increased relative risk of carditis -- a type of heart inflammation -- associated with Covid vaccine developed by US drugmaker Pfizer and China's CoronaVac, researchers have found.
The findings, published in Annals of Internal Medicine, show a significant increased risk in adolescents after the second dose.
Patients who received Pfizer were three times more likely to experience carditis than unvaccinated patients.
On the other hand, patients who received CoronaVac had a similar chance as unvaccinated patients to experience carditis.
Researchers from the University of Hong Kong also observed that risk increase associated with Pfizer's Covid vaccine was predominant in males and was more likely to be seen after the second dose.
"The vaccination strategies may need to continuously consider the risks and benefits for different sub-populations, rather than taking a aone-size-fits-all' approach," they suggested.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.